The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population
Vinicius Carrera Souza , Fernando Sabino Marques Monteiro , Fernando Cotait Maluf , Gustavo Werutsky , Vanessa de Carvalho Fabrício , Rosemarie Gidekel , Maria Natalia Gandur-Quiroga , Marcelo Roberto Pereira Freitas , Murilo Luz , Saul Campos-Gomez , Jose Augusto Rinck Junior , Diogo Assed Bastos , Juan Pablo Sade , Karine Martins da Trindade , Augusto Cesar de Andrade Mota , Roni de Carvalho Fernandes , Allan Omar Barillas Ruíz , Breno Dauster Pereira e Silva , Fernando Nunes Galvão de Oliveira , Hernan Javier Cutuli , André Poisl Fay
{"title":"The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population","authors":"Vinicius Carrera Souza , Fernando Sabino Marques Monteiro , Fernando Cotait Maluf , Gustavo Werutsky , Vanessa de Carvalho Fabrício , Rosemarie Gidekel , Maria Natalia Gandur-Quiroga , Marcelo Roberto Pereira Freitas , Murilo Luz , Saul Campos-Gomez , Jose Augusto Rinck Junior , Diogo Assed Bastos , Juan Pablo Sade , Karine Martins da Trindade , Augusto Cesar de Andrade Mota , Roni de Carvalho Fernandes , Allan Omar Barillas Ruíz , Breno Dauster Pereira e Silva , Fernando Nunes Galvão de Oliveira , Hernan Javier Cutuli , André Poisl Fay","doi":"10.1016/j.clgc.2024.102174","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.</p></div><div><h3>Patients and methods</h3><p>A multicenter retrospective cohort study from 2016 to 2019 of patients with mUC from several LACOG LATAM institutions. FGFR alterations were analyzed by real-time PCR and/or next-generation sequencing in tumor samples and clinicopathologic characteristics and survival outcomes data were collected. The prevalence of FGFR, patient characteristics, and treatment in real-world settings were summarized. Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate the associations of FGFR mutation and/or fusion status with median overall survival (mOS), median time to treatment failure (mTTF), and clinicopathological characteristics.</p></div><div><h3>Results</h3><p>In total, 222 patients were screened. Of these, 196 patients were considered eligible and were included in the analysis. FGFR mutations and/or fusions were found in 35 (17.9%) patients. There was no statistical difference in mOS and mTTF in FGFR-altered and non-altered patients (13.1 vs. 16.8 months, <em>P =</em> .20 and 3.9 vs. 4.1 months, <em>P =</em> .96, respectively). Bellmunt's prognostic model correctly predicted overall survival (<em>P =</em> .049).</p></div><div><h3>Conclusions</h3><p>This is the largest study evaluating the prevalence of FGFR alterations in patients with mUC in the LATAM population. FGFR alterations in mUC were found in 17.9% of the patients, and the presence of this biomarker was not associated with OS. We validated Bellmunt's prognostic model in this cohort.</p></div>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1558767324001459","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction
Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.
Patients and methods
A multicenter retrospective cohort study from 2016 to 2019 of patients with mUC from several LACOG LATAM institutions. FGFR alterations were analyzed by real-time PCR and/or next-generation sequencing in tumor samples and clinicopathologic characteristics and survival outcomes data were collected. The prevalence of FGFR, patient characteristics, and treatment in real-world settings were summarized. Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate the associations of FGFR mutation and/or fusion status with median overall survival (mOS), median time to treatment failure (mTTF), and clinicopathological characteristics.
Results
In total, 222 patients were screened. Of these, 196 patients were considered eligible and were included in the analysis. FGFR mutations and/or fusions were found in 35 (17.9%) patients. There was no statistical difference in mOS and mTTF in FGFR-altered and non-altered patients (13.1 vs. 16.8 months, P = .20 and 3.9 vs. 4.1 months, P = .96, respectively). Bellmunt's prognostic model correctly predicted overall survival (P = .049).
Conclusions
This is the largest study evaluating the prevalence of FGFR alterations in patients with mUC in the LATAM population. FGFR alterations in mUC were found in 17.9% of the patients, and the presence of this biomarker was not associated with OS. We validated Bellmunt's prognostic model in this cohort.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
